tooluniverse-antibody-engineering

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Antibody Engineering & Optimization

抗体工程与优化

AI-guided antibody optimization pipeline from preclinical lead to clinical candidate. Covers sequence humanization, structure modeling, affinity optimization, developability assessment, immunogenicity prediction, and manufacturing feasibility.
KEY PRINCIPLES:
  1. Report-first approach - Create optimization report before analysis
  2. Evidence-graded humanization - Score based on germline alignment and framework retention
  3. Developability-focused - Assess aggregation, stability, PTMs, immunogenicity
  4. Structure-guided - Use AlphaFold/PDB structures for CDR analysis
  5. Clinical precedent - Reference approved antibodies for validation
  6. Quantitative scoring - Developability score (0-100) combining multiple factors
  7. English-first queries - Always use English terms in tool calls, even if user writes in another language. Respond in user's language

AI引导的抗体优化流程,覆盖从临床前先导分子到临床候选药物的全阶段。包含序列人源化、结构建模、亲和力优化、成药性评估、免疫原性预测及生产可行性分析。
核心原则:
  1. 先报告后分析 - 在开展分析前先创建优化报告
  2. 循证分级人源化 - 基于种系序列比对和框架区保留情况打分
  3. 成药性导向 - 评估聚集性、稳定性、翻译后修饰(PTMs)及免疫原性
  4. 结构引导 - 利用AlphaFold/PDB结构进行CDR分析
  5. 临床先例参考 - 以已获批抗体作为验证依据
  6. 量化评分 - 结合多维度指标的成药性评分(0-100分)
  7. 工具调用优先英文 - 即使用户使用其他语言提问,工具调用时始终使用英文术语,以用户语言回复

When to Use

适用场景

Apply when user asks:
  • "Humanize this mouse antibody sequence"
  • "Optimize antibody affinity for [target]"
  • "Assess developability of this antibody"
  • "Predict immunogenicity risk for [sequence]"
  • "Engineer bispecific antibody against [targets]"
  • "Reduce aggregation in antibody formulation"
  • "Design pH-dependent binding antibody"
  • "Analyze CDR sequences and suggest mutations"

当用户提出以下需求时适用:
  • "将该鼠源抗体序列人源化"
  • "针对[靶点]优化抗体亲和力"
  • "评估该抗体的成药性"
  • "预测[序列]的免疫原性风险"
  • "针对[靶点]设计双特异性抗体"
  • "降低抗体制剂的聚集性"
  • "设计pH依赖性结合抗体"
  • "分析CDR序列并提出突变建议"

Critical Workflow Requirements

关键工作流要求

1. Report-First Approach (MANDATORY)

1. 先报告后分析(强制要求)

  1. Create the report file FIRST:
    • File name:
      antibody_optimization_report.md
    • Initialize with section headers
    • Add placeholder:
      [Analyzing...]
  2. Progressively update as analysis completes
  3. Output separate files:
    • optimized_sequences.fasta
      - All optimized variants
    • humanization_comparison.csv
      - Before/after comparison
    • developability_assessment.csv
      - Detailed scores
  1. 首先创建报告文件:
    • 文件名:
      antibody_optimization_report.md
    • 初始化时添加章节标题
    • 加入占位符:
      [分析中...]
  2. 随分析进度逐步更新
  3. 输出独立文件:
    • optimized_sequences.fasta
      - 所有优化变体序列
    • humanization_comparison.csv
      - 优化前后对比数据
    • developability_assessment.csv
      - 详细成药性评分

2. Documentation Standards (MANDATORY)

2. 文档规范(强制要求)

Every optimization MUST include:
markdown
undefined
每一项优化必须包含如下格式内容:
markdown
undefined

Optimized Variant: VH_Humanized_v1

优化变体: VH_Humanized_v1

Original Sequence: EVQLVESGGGLVQPGG... (mouse) Humanized Sequence: EVQLVQSGAEVKKPGA... (human framework) Humanization Score: 87% human framework CDR Preservation: 100% (all CDR residues retained)
Metrics:
MetricOriginalOptimizedChange
Humanness62%87%+25%
Aggregation risk0.580.32-45%
Predicted KD5.2 nM3.8 nM+27% affinity
ImmunogenicityHighLow-65%
Source: IMGT germline analysis, IEDB predictions

---
原始序列: EVQLVESGGGLVQPGG... (鼠源) 人源化序列: EVQLVQSGAEVKKPGA... (人源框架区) 人源化得分: 87% 人源框架区 CDR保留率: 100% (所有CDR残基均保留)
指标对比:
指标原始序列优化后序列变化
人源化程度62%87%+25%
聚集风险0.580.32-45%
预测KD值5.2 nM3.8 nM亲和力提升+27%
免疫原性-65%
来源: IMGT种系分析, IEDB预测

---

Phase 0: Tool Verification

阶段0: 工具验证

Required Tools

必备工具

ToolPurposeCategory
IMGT_search_genes
Germline gene identificationHumanization
IMGT_get_sequence
Human framework sequencesHumanization
SAbDab_search_structures
Antibody structure precedentsStructure
TheraSAbDab_search_by_target
Clinical antibody benchmarksValidation
AlphaFold_get_prediction
Structure modelingStructure
iedb_search_epitopes
Epitope identificationImmunogenicity
iedb_search_bcell
B-cell epitope predictionImmunogenicity
UniProt_get_protein_by_accession
Target antigen informationTarget
STRING_get_interactions
Protein interaction networkBispecifics
PubMed_search
Literature precedentsValidation

工具用途分类
IMGT_search_genes
种系基因识别人源化
IMGT_get_sequence
获取人源框架区序列人源化
SAbDab_search_structures
抗体结构先例查询结构分析
TheraSAbDab_search_by_target
临床抗体基准参考验证
AlphaFold_get_prediction
结构建模结构分析
iedb_search_epitopes
表位识别免疫原性
iedb_search_bcell
B细胞表位预测免疫原性
UniProt_get_protein_by_accession
靶点抗原信息获取靶点分析
STRING_get_interactions
蛋白质相互作用网络分析双特异性抗体
PubMed_search
文献先例查询验证

Workflow Overview

工作流概览

Phase 1: Input Analysis & Characterization
├── Sequence annotation (CDRs, framework)
├── Species identification
├── Target antigen identification
├── Clinical precedent search
└── OUTPUT: Input characterization
Phase 2: Humanization Strategy
├── Germline gene alignment (IMGT)
├── Framework selection
├── CDR grafting design
├── Backmutation identification
└── OUTPUT: Humanization plan
Phase 3: Structure Modeling & Analysis
├── AlphaFold prediction
├── CDR conformation analysis
├── Epitope mapping
├── Interface analysis
└── OUTPUT: Structural assessment
Phase 4: Affinity Optimization
├── In silico mutation screening
├── CDR optimization strategies
├── Interface improvement
└── OUTPUT: Affinity variants
Phase 5: Developability Assessment
├── Aggregation propensity
├── PTM site identification
├── Stability prediction
├── Expression prediction
└── OUTPUT: Developability score
Phase 6: Immunogenicity Prediction
├── MHC-II epitope prediction (IEDB)
├── T-cell epitope risk
├── Aggregation-related immunogenicity
└── OUTPUT: Immunogenicity risk score
Phase 7: Manufacturing Feasibility
├── Expression level prediction
├── Purification considerations
├── Formulation stability
└── OUTPUT: Manufacturing assessment
Phase 8: Final Report & Recommendations
├── Ranked variant list
├── Experimental validation plan
├── Next steps
└── OUTPUT: Comprehensive report

阶段1: 输入分析与特征表征
├── 序列注释(CDR、框架区)
├── 物种识别
├── 靶点抗原表征
├── 临床先例查询
└── 输出: 输入特征表征结果
阶段2: 人源化策略
├── 种系基因比对(IMGT)
├── 框架区选择
├── CDR移植设计
├── 回复突变识别
└── 输出: 人源化方案
阶段3: 结构建模与分析
├── AlphaFold结构预测
├── CDR构象分析
├── 表位定位
├── 结合界面分析
└── 输出: 结构评估结果
阶段4: 亲和力优化
├── 计算突变筛选
├── CDR优化策略
├── 结合界面改进
└── 输出: 亲和力优化变体
阶段5: 成药性评估
├── 聚集倾向性分析
├── PTM位点识别
├── 稳定性预测
├── 表达量预测
└── 输出: 成药性评分
阶段6: 免疫原性预测
├── MHC-II表位预测(IEDB)
├── T细胞表位风险评估
├── 聚集相关免疫原性分析
└── 输出: 免疫原性风险评分
阶段7: 生产可行性分析
├── 表达量预测
├── 纯化方案考量
├── 制剂稳定性分析
└── 输出: 生产评估结果
阶段8: 最终报告与建议
├── 变体排名列表
├── 实验验证方案
├── 后续步骤规划
└── 输出: 综合报告

Phase 1: Input Analysis & Characterization

阶段1: 输入分析与特征表征

1.1 Sequence Annotation

1.1 序列注释

python
def annotate_antibody_sequence(sequence):
    """Annotate antibody sequence with CDRs and framework regions."""

    # Use IMGT numbering scheme (standard for antibodies)
    # CDR definitions (IMGT):
    # CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117
    # CDR-L1: 27-38, CDR-L2: 56-65, CDR-L3: 105-117

    annotation = {
        'sequence': sequence,
        'length': len(sequence),
        'regions': {
            'FR1': sequence[0:26],
            'CDR1': sequence[26:38],
            'FR2': sequence[38:55],
            'CDR2': sequence[55:65],
            'FR3': sequence[65:104],
            'CDR3': sequence[104:117],
            'FR4': sequence[117:]
        }
    }

    return annotation
python
def annotate_antibody_sequence(sequence):
    """为抗体序列添加CDR和框架区注释。"""

    # 使用IMGT编号体系(抗体领域标准)
    # CDR定义(IMGT):
    # CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117
    # CDR-L1: 27-38, CDR-L2: 56-65, CDR-L3: 105-117

    annotation = {
        'sequence': sequence,
        'length': len(sequence),
        'regions': {
            'FR1': sequence[0:26],
            'CDR1': sequence[26:38],
            'FR2': sequence[38:55],
            'CDR2': sequence[55:65],
            'FR3': sequence[65:104],
            'CDR3': sequence[104:117],
            'FR4': sequence[117:]
        }
    }

    return annotation

1.2 Species & Germline Identification

1.2 物种与种系基因识别

python
def identify_germline(tu, vh_sequence, vl_sequence):
    """Identify germline genes for VH and VL chains using IMGT."""

    # Search for human germline genes
    vh_germlines = tu.tools.IMGT_search_genes(
        gene_type="IGHV",
        species="Homo sapiens"
    )

    vl_germlines = tu.tools.IMGT_search_genes(
        gene_type="IGKV",  # or IGLV for lambda
        species="Homo sapiens"
    )

    # Get sequences for top matches
    # Calculate identity % for each germline
    # Return closest matches

    return {
        'vh_germline': 'IGHV1-69*01',
        'vh_identity': 87.2,
        'vl_germline': 'IGKV1-39*01',
        'vl_identity': 89.5
    }
python
def identify_germline(tu, vh_sequence, vl_sequence):
    """利用IMGT识别VH和VL链的种系基因。"""

    # 搜索人源种系基因
    vh_germlines = tu.tools.IMGT_search_genes(
        gene_type="IGHV",
        species="Homo sapiens"
    )

    vl_germlines = tu.tools.IMGT_search_genes(
        gene_type="IGKV",  # lambda链使用IGLV
        species="Homo sapiens"
    )

    # 获取匹配度最高的序列
    # 计算每个种系基因的序列一致性
    # 返回最接近的匹配结果

    return {
        'vh_germline': 'IGHV1-69*01',
        'vh_identity': 87.2,
        'vl_germline': 'IGKV1-39*01',
        'vl_identity': 89.5
    }

1.3 Clinical Precedent Search

1.3 临床先例查询

python
def search_clinical_precedents(tu, target_antigen):
    """Find approved/clinical antibodies against same target."""

    # Search Thera-SAbDab for clinical antibodies
    therapeutics = tu.tools.TheraSAbDab_search_by_target(
        target=target_antigen
    )

    approved = [ab for ab in therapeutics if ab['phase'] == 'Approved']
    clinical = [ab for ab in therapeutics if 'Phase' in ab['phase']]

    return {
        'approved_count': len(approved),
        'clinical_count': len(clinical),
        'examples': approved[:3],
        'insights': extract_design_patterns(approved)
    }
python
def search_clinical_precedents(tu, target_antigen):
    """查找针对同一靶点的已获批/临床阶段抗体。"""

    # 在Thera-SAbDab中搜索临床抗体
    therapeutics = tu.tools.TheraSAbDab_search_by_target(
        target=target_antigen
    )

    approved = [ab for ab in therapeutics if ab['phase'] == 'Approved']
    clinical = [ab for ab in therapeutics if 'Phase' in ab['phase']]

    return {
        'approved_count': len(approved),
        'clinical_count': len(clinical),
        'examples': approved[:3],
        'insights': extract_design_patterns(approved)
    }

1.4 Output for Report

1.4 报告输出内容

markdown
undefined
markdown
undefined

1. Input Characterization

1. 输入特征表征

1.1 Sequence Information

1.1 序列信息

PropertyHeavy Chain (VH)Light Chain (VL)
Length118 aa107 aa
SpeciesMouse (Mus musculus)Mouse (Mus musculus)
Humanness62%68%
Closest human germlineIGHV1-69*01 (87% identity)IGKV1-39*01 (90% identity)
属性重链(VH)轻链(VL)
长度118 aa107 aa
物种来源小鼠(Mus musculus)小鼠(Mus musculus)
人源化程度62%68%
最接近的人源种系基因IGHV1-69*01(87%一致性)IGKV1-39*01(90%一致性)

1.2 CDR Annotation (IMGT Numbering)

1.2 CDR注释(IMGT编号)

Heavy Chain:
  • FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128
CDR Sequences:
CDRSequenceLengthCanonical Class
CDR-H1GYTFTSYYMH10H1-13-1
CDR-H2GIIPIFGTANY11H2-10-1
CDR-H3ARDDGSYSPFDYWG14- (unique)
CDR-L1RASQSISSYLN11L1-11-1
CDR-L2AASSLQS7L2-8-1
CDR-L3QQSYSTPLT9L3-9-cis7-1
重链:
  • FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128
CDR序列:
CDR序列长度经典构象类别
CDR-H1GYTFTSYYMH10H1-13-1
CDR-H2GIIPIFGTANY11H2-10-1
CDR-H3ARDDGSYSPFDYWG14-(独特构象)
CDR-L1RASQSISSYLN11L1-11-1
CDR-L2AASSLQS7L2-8-1
CDR-L3QQSYSTPLT9L3-9-cis7-1

1.3 Target Information

1.3 靶点信息

PropertyValue
TargetPD-L1 (Programmed death-ligand 1)
UniProtQ9NZQ7
FunctionImmune checkpoint, inhibits T-cell activation
Disease relevanceCancer immunotherapy target
属性数值
靶点PD-L1(程序性死亡配体1)
UniProt编号Q9NZQ7
功能免疫检查点,抑制T细胞活化
疾病相关性肿瘤免疫治疗靶点

1.4 Clinical Precedents

1.4 临床先例

Approved antibodies targeting PD-L1:
  1. Atezolizumab (Tecentriq) - IgG1, approved 2016
  2. Durvalumab (Imfinzi) - IgG1, approved 2017
  3. Avelumab (Bavencio) - IgG1, approved 2017
Key insights: All approved anti-PD-L1 antibodies use human IgG1 scaffolds with effector function modifications.
Source: TheraSAbDab, UniProt

---
已获批的抗PD-L1抗体:
  1. Atezolizumab(Tecentriq)- IgG1,2016年获批
  2. Durvalumab(Imfinzi)- IgG1,2017年获批
  3. Avelumab(Bavencio)- IgG1,2017年获批
关键启示: 所有已获批抗PD-L1抗体均采用人源IgG1骨架,并对效应功能进行了修饰。
来源: TheraSAbDab, UniProt

---

Phase 2: Humanization Strategy

阶段2: 人源化策略

2.1 Framework Selection

2.1 框架区选择

python
def select_human_framework(tu, mouse_sequence, cdr_sequences):
    """Select optimal human framework for CDR grafting."""

    # Search IMGT for human germline genes
    vh_genes = tu.tools.IMGT_search_genes(
        gene_type="IGHV",
        species="Homo sapiens"
    )

    # For each candidate framework:
    # 1. Calculate sequence identity to mouse FR
    # 2. Check CDR canonical class compatibility
    # 3. Assess structural compatibility
    # 4. Consider clinical precedents

    candidates = []
    for gene in vh_genes[:20]:  # Top 20 human germlines
        gene_seq = tu.tools.IMGT_get_sequence(
            accession=gene['accession'],
            format='fasta'
        )

        score = calculate_framework_score(
            mouse_fr=extract_framework(mouse_sequence),
            human_fr=extract_framework(gene_seq),
            cdr_compatibility=check_cdr_compatibility(cdr_sequences, gene_seq)
        )

        candidates.append({
            'germline': gene['name'],
            'identity': score['identity'],
            'cdr_compatibility': score['cdr_compatibility'],
            'clinical_use': count_clinical_uses(gene['name']),
            'overall_score': score['total']
        })

    # Sort by overall score
    return sorted(candidates, key=lambda x: x['overall_score'], reverse=True)
python
def select_human_framework(tu, mouse_sequence, cdr_sequences):
    """为CDR移植选择最优人源框架区。"""

    # 在IMGT中搜索人源种系基因
    vh_genes = tu.tools.IMGT_search_genes(
        gene_type="IGHV",
        species="Homo sapiens"
    )

    # 对每个候选框架区:
    # 1. 计算与鼠源框架区的序列一致性
    # 2. 检查CDR经典构象兼容性
    # 3. 评估结构兼容性
    # 4. 参考临床应用先例

    candidates = []
    for gene in vh_genes[:20]:  # 前20种人源种系基因
        gene_seq = tu.tools.IMGT_get_sequence(
            accession=gene['accession'],
            format='fasta'
        )

        score = calculate_framework_score(
            mouse_fr=extract_framework(mouse_sequence),
            human_fr=extract_framework(gene_seq),
            cdr_compatibility=check_cdr_compatibility(cdr_sequences, gene_seq)
        )

        candidates.append({
            'germline': gene['name'],
            'identity': score['identity'],
            'cdr_compatibility': score['cdr_compatibility'],
            'clinical_use': count_clinical_uses(gene['name']),
            'overall_score': score['total']
        })

    # 按综合得分排序
    return sorted(candidates, key=lambda x: x['overall_score'], reverse=True)

2.2 CDR Grafting Design

2.2 CDR移植设计

python
def design_cdr_grafting(mouse_sequence, human_framework, cdr_sequences):
    """Design CDR grafting with backmutation identification."""

    # Graft mouse CDRs onto human framework
    grafted_sequence = graft_cdrs(
        human_framework=human_framework,
        mouse_cdrs=cdr_sequences
    )

    # Identify Vernier zone residues (affect CDR conformation)
    vernier_residues = [2, 27, 28, 29, 30, 47, 48, 67, 69, 71, 78, 93, 94]

    # Identify potential backmutations
    backmutations = []
    for pos in vernier_residues:
        if mouse_sequence[pos] != human_framework[pos]:
            backmutations.append({
                'position': pos,
                'human_aa': human_framework[pos],
                'mouse_aa': mouse_sequence[pos],
                'reason': 'Vernier zone - may affect CDR conformation',
                'priority': 'High' if pos in [27, 29, 30, 48] else 'Medium'
            })

    return {
        'grafted_sequence': grafted_sequence,
        'backmutations': backmutations,
        'humanness_score': calculate_humanness(grafted_sequence)
    }
python
def design_cdr_grafting(mouse_sequence, human_framework, cdr_sequences):
    """设计CDR移植方案并识别回复突变位点。"""

    # 将鼠源CDR移植到人源框架区
    grafted_sequence = graft_cdrs(
        human_framework=human_framework,
        mouse_cdrs=cdr_sequences
    )

    # 识别Vernier区残基(影响CDR构象)
    vernier_residues = [2, 27, 28, 29, 30, 47, 48, 67, 69, 71, 78, 93, 94]

    # 识别潜在回复突变位点
    backmutations = []
    for pos in vernier_residues:
        if mouse_sequence[pos] != human_framework[pos]:
            backmutations.append({
                'position': pos,
                'human_aa': human_framework[pos],
                'mouse_aa': mouse_sequence[pos],
                'reason': 'Vernier区 - 可能影响CDR构象',
                'priority': '高' if pos in [27, 29, 30, 48] else '中'
            })

    return {
        'grafted_sequence': grafted_sequence,
        'backmutations': backmutations,
        'humanness_score': calculate_humanness(grafted_sequence)
    }

2.3 Humanization Scoring

2.3 人源化评分

python
def calculate_humanization_score(sequence, human_germline):
    """Calculate comprehensive humanization score."""

    # Framework humanness (% identity to human germline)
    fr_identity = calculate_framework_identity(sequence, human_germline)

    # T-cell epitope content (lower is better)
    tcell_epitope_count = predict_tcell_epitopes(sequence)

    # Unusual residues in human context
    unusual_residues = count_unusual_residues(sequence)

    # Aggregation hotspots
    aggregation_motifs = find_aggregation_motifs(sequence)

    score = {
        'framework_humanness': fr_identity,  # 0-100%
        'cdr_preservation': 100,  # Always 100% initially
        'tcell_epitopes': tcell_epitope_count,
        'unusual_residues': unusual_residues,
        'aggregation_risk': len(aggregation_motifs),
        'overall_score': calculate_weighted_score(
            fr_identity, tcell_epitope_count, unusual_residues, aggregation_motifs
        )
    }

    return score
python
def calculate_humanization_score(sequence, human_germline):
    """计算综合人源化评分。"""

    # 框架区人源化程度(与人源种系基因的一致性百分比)
    fr_identity = calculate_framework_identity(sequence, human_germline)

    # T细胞表位含量(越少越好)
    tcell_epitope_count = predict_tcell_epitopes(sequence)

    # 人源背景下的异常残基数量
    unusual_residues = count_unusual_residues(sequence)

    # 聚集热点区域
    aggregation_motifs = find_aggregation_motifs(sequence)

    score = {
        'framework_humanness': fr_identity,  # 0-100%
        'cdr_preservation': 100,  # 初始阶段始终为100%
        'tcell_epitopes': tcell_epitope_count,
        'unusual_residues': unusual_residues,
        'aggregation_risk': len(aggregation_motifs),
        'overall_score': calculate_weighted_score(
            fr_identity, tcell_epitope_count, unusual_residues, aggregation_motifs
        )
    }

    return score

2.4 Output for Report

2.4 报告输出内容

markdown
undefined
markdown
undefined

2. Humanization Strategy

2. 人源化策略

2.1 Framework Selection

2.1 框架区选择

Selected Human Frameworks:
ChainGermlineIdentityCDR CompatibilityClinical UseScore
VHIGHV1-69*0187.2%Excellent127 antibodies94/100
VLIGKV1-39*0189.5%Excellent89 antibodies92/100
Rationale:
  • IGHV1-69*01: Most frequently used human germline in therapeutic antibodies
  • High sequence identity minimizes risk of affinity loss
  • Excellent CDR canonical class compatibility
  • Proven clinical track record
选定的人源框架区:
种系基因序列一致性CDR兼容性临床应用次数得分
VHIGHV1-69*0187.2%优秀127种抗体94/100
VLIGKV1-39*0189.5%优秀89种抗体92/100
选择依据:
  • IGHV1-69*01: 治疗性抗体中使用最频繁的人源种系基因
  • 高序列一致性可最小化亲和力损失风险
  • 与CDR经典构象高度兼容
  • 具备成熟的临床应用记录

2.2 CDR Grafting Design

2.2 CDR移植设计

Grafting Strategy: Direct CDR transfer with Vernier zone optimization
RegionSourceSequenceRationale
FR1IGHV1-69*01EVQLVQSGAEVKKPGA...Human framework
CDR-H1MouseGYTFTSYYMHRetain binding
FR2IGHV1-69*01VKWVRQAPGQGLE...Human framework
CDR-H2MouseGIIPIFGTANYRetain binding
FR3IGHV1-69*01RVTMTTDTSTSTYME...Human framework
CDR-H3MouseARDDGSYSPFDYWGRetain binding
FR4IGHJ4*01WGQGTLVTVSSHuman framework
移植策略: 直接CDR移植结合Vernier区优化
区域来源序列依据
FR1IGHV1-69*01EVQLVQSGAEVKKPGA...人源框架区
CDR-H1鼠源GYTFTSYYMH保留结合活性
FR2IGHV1-69*01VKWVRQAPGQGLE...人源框架区
CDR-H2鼠源GIIPIFGTANY保留结合活性
FR3IGHV1-69*01RVTMTTDTSTSTYME...人源框架区
CDR-H3鼠源ARDDGSYSPFDYWG保留结合活性
FR4IGHJ4*01WGQGTLVTVSS人源框架区

2.3 Backmutation Analysis

2.3 回复突变分析

Identified Vernier Zone Residues (may require backmutation):
PositionHumanMouseRegionImpactPriority
27TACDR-H1 boundaryCDR conformationHigh
48IVFR2VH-VL interfaceHigh
67ASFR3CDR-H2 supportMedium
71RKFR3CDR-H2 supportMedium
93ATFR3CDR-H3 baseMedium
Recommendation: Test versions with/without backmutations at positions 27 and 48
识别的Vernier区残基(可能需要回复突变):
位置人源残基鼠源残基区域影响优先级
27TACDR-H1边界CDR构象
48IVFR2VH-VL界面
67ASFR3CDR-H2支撑区
71RKFR3CDR-H2支撑区
93ATFR3CDR-H3基部
建议: 测试包含/不包含27和48位回复突变的变体

2.4 Humanized Sequences

2.4 人源化序列

Version 1: Full humanization (no backmutations)
>VH_Humanized_v1 | 87% human framework
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
Version 2: With key backmutations (positions 27, 48)
>VH_Humanized_v2 | 85% human framework + backmutations
EVQLVQSGAEVKKPGASVKVSCKASGYAFTSYYMHWVRQAPGQGLEWMVGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
Humanization Metrics:
MetricOriginal (Mouse)v1 (Full)v2 (Backmut)
Framework humanness62%87%85%
CDR preservation100%100%100%
Vernier zone matchMouseHumanMixed
Predicted affinityBaseline60-80%80-100%
Source: IMGT germline database, CDR analysis

---
版本1: 完全人源化(无回复突变)
>VH_Humanized_v1 | 87%人源框架区
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
版本2: 包含关键回复突变(27、48位)
>VH_Humanized_v2 | 85%人源框架区 + 回复突变
EVQLVQSGAEVKKPGASVKVSCKASGYAFTSYYMHWVRQAPGQGLEWMVGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
人源化指标:
指标原始鼠源序列v1(完全人源化)v2(含回复突变)
框架区人源化程度62%87%85%
CDR保留率100%100%100%
Vernier区匹配度鼠源人源混合
预测亲和力基线水平60-80%基线80-100%基线
来源: IMGT种系数据库, CDR分析

---

Phase 3: Structure Modeling & Analysis

阶段3: 结构建模与分析

3.1 AlphaFold Structure Prediction

3.1 AlphaFold结构预测

python
def predict_antibody_structure(tu, vh_sequence, vl_sequence):
    """Predict antibody Fv structure using AlphaFold."""

    # Combine VH and VL with linker
    fv_sequence = vh_sequence + ":" + vl_sequence  # AlphaFold uses : for chain separator

    # Predict structure
    prediction = tu.tools.AlphaFold_get_prediction(
        sequence=fv_sequence,
        return_format='pdb'
    )

    # Extract pLDDT scores
    plddt_scores = extract_plddt(prediction)

    # Analyze by region
    regions = {
        'VH_FR': np.mean([plddt_scores[i] for i in range(0, 26)]),
        'CDR_H1': np.mean([plddt_scores[i] for i in range(26, 38)]),
        'CDR_H2': np.mean([plddt_scores[i] for i in range(55, 65)]),
        'CDR_H3': np.mean([plddt_scores[i] for i in range(104, 117)]),
        'VL_FR': np.mean([plddt_scores[i] for i in range(len(vh_sequence), len(vh_sequence)+26)]),
        'CDR_L1': np.mean([plddt_scores[i] for i in range(len(vh_sequence)+26, len(vh_sequence)+38)]),
    }

    return {
        'structure': prediction,
        'mean_plddt': np.mean(plddt_scores),
        'regional_plddt': regions,
        'cdr_confidence': np.mean([regions['CDR_H1'], regions['CDR_H2'], regions['CDR_H3']])
    }
python
def predict_antibody_structure(tu, vh_sequence, vl_sequence):
    """利用AlphaFold预测抗体Fv区结构。"""

    # 用连接子拼接VH和VL序列
    fv_sequence = vh_sequence + ":" + vl_sequence  # AlphaFold使用:作为链分隔符

    # 预测结构
    prediction = tu.tools.AlphaFold_get_prediction(
        sequence=fv_sequence,
        return_format='pdb'
    )

    # 提取pLDDT评分
    plddt_scores = extract_plddt(prediction)

    # 按区域分析
    regions = {
        'VH_FR': np.mean([plddt_scores[i] for i in range(0, 26)]),
        'CDR_H1': np.mean([plddt_scores[i] for i in range(26, 38)]),
        'CDR_H2': np.mean([plddt_scores[i] for i in range(55, 65)]),
        'CDR_H3': np.mean([plddt_scores[i] for i in range(104, 117)]),
        'VL_FR': np.mean([plddt_scores[i] for i in range(len(vh_sequence), len(vh_sequence)+26)]),
        'CDR_L1': np.mean([plddt_scores[i] for i in range(len(vh_sequence)+26, len(vh_sequence)+38)]),
    }

    return {
        'structure': prediction,
        'mean_plddt': np.mean(plddt_scores),
        'regional_plddt': regions,
        'cdr_confidence': np.mean([regions['CDR_H1'], regions['CDR_H2'], regions['CDR_H3']])
    }

3.2 CDR Conformation Analysis

3.2 CDR构象分析

python
def analyze_cdr_conformation(structure):
    """Analyze CDR loop conformations and canonical classes."""

    # Extract CDR coordinates
    cdr_coords = extract_cdr_regions(structure)

    # Classify canonical structures
    cdr_classes = {
        'CDR-H1': classify_canonical_structure(cdr_coords['H1']),
        'CDR-H2': classify_canonical_structure(cdr_coords['H2']),
        'CDR-H3': 'Non-canonical (14 aa)',  # Usually unique
        'CDR-L1': classify_canonical_structure(cdr_coords['L1']),
        'CDR-L2': classify_canonical_structure(cdr_coords['L2']),
        'CDR-L3': classify_canonical_structure(cdr_coords['L3'])
    }

    # Calculate RMSD to known canonical structures
    rmsd_values = calculate_canonical_rmsd(cdr_coords, cdr_classes)

    return {
        'classes': cdr_classes,
        'rmsd': rmsd_values,
        'confidence': assess_conformation_confidence(rmsd_values)
    }
python
def analyze_cdr_conformation(structure):
    """分析CDR环构象及经典构象类别。"""

    # 提取CDR坐标
    cdr_coords = extract_cdr_regions(structure)

    # 分类经典构象
    cdr_classes = {
        'CDR-H1': classify_canonical_structure(cdr_coords['H1']),
        'CDR-H2': classify_canonical_structure(cdr_coords['H2']),
        'CDR-H3': '非经典构象(14 aa)',  # 通常为独特构象
        'CDR-L1': classify_canonical_structure(cdr_coords['L1']),
        'CDR-L2': classify_canonical_structure(cdr_coords['L2']),
        'CDR-L3': classify_canonical_structure(cdr_coords['L3'])
    }

    # 计算与已知经典构象的RMSD
    rmsd_values = calculate_canonical_rmsd(cdr_coords, cdr_classes)

    return {
        'classes': cdr_classes,
        'rmsd': rmsd_values,
        'confidence': assess_conformation_confidence(rmsd_values)
    }

3.3 Epitope Mapping

3.3 表位定位

python
def map_epitope(tu, target_protein, antibody_structure):
    """Identify epitope on target protein."""

    # Get target structure or predict
    target_info = tu.tools.UniProt_get_protein_by_accession(
        accession=target_protein
    )

    # Search for known epitopes
    epitopes = tu.tools.iedb_search_epitopes(
        sequence_contains=target_protein,
        structure_type="Linear peptide",
        limit=20
    )

    # Search for structural antibody complexes
    sabdab_results = tu.tools.SAbDab_search_structures(
        query=target_info['protein_name']
    )

    # Analyze binding interface
    interface = {
        'epitope_candidates': epitopes,
        'structural_precedents': sabdab_results,
        'predicted_interface': predict_binding_interface(antibody_structure)
    }

    return interface
python
def map_epitope(tu, target_protein, antibody_structure):
    """识别靶点蛋白上的表位。"""

    # 获取或预测靶点结构
    target_info = tu.tools.UniProt_get_protein_by_accession(
        accession=target_protein
    )

    # 搜索已知表位
    epitopes = tu.tools.iedb_search_epitopes(
        sequence_contains=target_protein,
        structure_type="Linear peptide",
        limit=20
    )

    # 搜索已解析的抗体-靶点复合物结构
    sabdab_results = tu.tools.SAbDab_search_structures(
        query=target_info['protein_name']
    )

    # 分析结合界面
    interface = {
        'epitope_candidates': epitopes,
        'structural_precedents': sabdab_results,
        'predicted_interface': predict_binding_interface(antibody_structure)
    }

    return interface

3.4 Output for Report

3.4 报告输出内容

markdown
undefined
markdown
undefined

3. Structure Modeling & Analysis

3. 结构建模与分析

3.1 AlphaFold Predictions

3.1 AlphaFold预测结果

Structure Quality:
VariantMean pLDDTVH pLDDTVL pLDDTCDR pLDDTConfidence
Original (Mouse)89.291.488.785.3High
VH_Humanized_v187.889.688.283.1High
VH_Humanized_v288.990.888.584.8High
Regional Confidence (v2):
  • Framework regions: 92.3 (very high)
  • CDR-H1, H2, L1, L2: 87-91 (high)
  • CDR-H3: 78.4 (moderate - expected for unique CDR-H3)
  • VH-VL interface: 90.1 (high)
结构质量:
变体平均pLDDTVH pLDDTVL pLDDTCDR pLDDT置信度
原始鼠源序列89.291.488.785.3
VH_Humanized_v187.889.688.283.1
VH_Humanized_v288.990.888.584.8
区域置信度(v2变体):
  • 框架区: 92.3(极高)
  • CDR-H1、H2、L1、L2: 87-91(高)
  • CDR-H3: 78.4(中等 - 独特CDR-H3的正常情况)
  • VH-VL界面: 90.1(高)

3.2 CDR Conformation Analysis

3.2 CDR构象分析

Canonical Classes (Humanized v2):
CDRLengthCanonical ClassRMSD to ClassStatus
CDR-H110H1-13-10.8 Å✓ Maintained
CDR-H211H2-10-11.1 Å✓ Maintained
CDR-H314Non-canonicalN/AUnique structure
CDR-L111L1-11-10.9 Å✓ Maintained
CDR-L27L2-8-10.7 Å✓ Maintained
CDR-L39L3-9-cis7-11.0 Å✓ Maintained
Assessment: All CDR conformations well-preserved in humanized variants. Low RMSD values indicate minimal structural perturbation from humanization.
经典构象类别(人源化v2变体):
CDR长度经典构象类别与类别的RMSD状态
CDR-H110H1-13-10.8 Å✓ 构象保留
CDR-H211H2-10-11.1 Å✓ 构象保留
CDR-H314非经典构象N/A独特构象
CDR-L111L1-11-10.9 Å✓ 构象保留
CDR-L27L2-8-10.7 Å✓ 构象保留
CDR-L39L3-9-cis7-11.0 Å✓ 构象保留
评估: 人源化变体中所有CDR构象均得到良好保留。低RMSD值表明人源化对结构的干扰极小。

3.3 Epitope Analysis

3.3 表位分析

Known PD-L1 Epitopes (IEDB):
EpitopeSequencePositionBinding AntibodiesConservation
Epitope 1LQDAG...VPEPP19-113Durvalumab, Avelumab98%
Epitope 2FTVT...PGPN54-68Atezolizumab100%
Epitope 3RLEDL...NVSI115-127Research Abs95%
Predicted Binding Interface:
  • Primary contact residues: CDR-H3 (70%), CDR-H1 (15%), CDR-H2 (10%)
  • Secondary contacts: CDR-L3 (5%)
  • Estimated buried surface area: 820 Ų
已知PD-L1表位(IEDB):
表位序列位置结合抗体保守性
表位1LQDAG...VPEPP19-113Durvalumab、Avelumab98%
表位2FTVT...PGPN54-68Atezolizumab100%
表位3RLEDL...NVSI115-127研究用抗体95%
预测结合界面:
  • 主要接触残基: CDR-H3(70%)、CDR-H1(15%)、CDR-H2(10%)
  • 次要接触残基: CDR-L3(5%)
  • 预估掩埋表面积: 820 Ų

3.4 Structural Comparison

3.4 结构对比

Superposition with Clinical Antibodies (SAbDab):
ReferencePDB IDVH RMSDVL RMSDCDR-H3 RMSDNotes
Atezolizumab5X8L1.2 Å1.4 Å2.8 ÅSimilar approach angle
Durvalumab5X8M1.8 Å1.5 Å3.4 ÅDifferent epitope
Research Ab5C3T0.9 Å1.1 Å1.5 ÅVery similar
Source: AlphaFold, IEDB, SAbDab

---
与临床抗体的结构叠加(SAbDab):
参考抗体PDB编号VH RMSDVL RMSDCDR-H3 RMSD说明
Atezolizumab5X8L1.2 Å1.4 Å2.8 Å结合角度相似
Durvalumab5X8M1.8 Å1.5 Å3.4 Å结合表位不同
研究用抗体5C3T0.9 Å1.1 Å1.5 Å结构高度相似
来源: AlphaFold, IEDB, SAbDab

---

Phase 4: Affinity Optimization

阶段4: 亲和力优化

4.1 In Silico Mutation Screening

4.1 计算突变筛选

python
def design_affinity_variants(antibody_structure, target_structure):
    """Design affinity maturation variants using computational screening."""

    # Identify interface residues
    interface_residues = identify_interface_residues(
        antibody_structure,
        target_structure,
        distance_cutoff=4.5  # Angstroms
    )

    # Focus on CDR residues
    cdr_interface = [res for res in interface_residues if is_cdr_residue(res)]

    # Design mutations for each position
    variants = []
    for position in cdr_interface:
        # Try all amino acids except original
        for aa in 'ACDEFGHIKLMNPQRSTVWY':
            if aa != antibody_structure.sequence[position]:
                predicted_ddg = predict_binding_energy_change(
                    structure=antibody_structure,
                    mutation=f"{antibody_structure.sequence[position]}{position}{aa}"
                )

                if predicted_ddg < -0.5:  # Favorable change (more negative = better)
                    variants.append({
                        'position': position,
                        'original': antibody_structure.sequence[position],
                        'mutant': aa,
                        'predicted_ddg': predicted_ddg,
                        'predicted_kd_fold': calculate_kd_change(predicted_ddg)
                    })

    # Rank by predicted improvement
    return sorted(variants, key=lambda x: x['predicted_ddg'])
python
def design_affinity_variants(antibody_structure, target_structure):
    """通过计算筛选设计亲和力成熟变体。"""

    # 识别结合界面残基
    interface_residues = identify_interface_residues(
        antibody_structure,
        target_structure,
        distance_cutoff=4.5  # 埃
    )

    # 聚焦CDR区残基
    cdr_interface = [res for res in interface_residues if is_cdr_residue(res)]

    # 为每个位置设计突变
    variants = []
    for position in cdr_interface:
        # 尝试除原始残基外的所有氨基酸
        for aa in 'ACDEFGHIKLMNPQRSTVWY':
            if aa != antibody_structure.sequence[position]:
                predicted_ddg = predict_binding_energy_change(
                    structure=antibody_structure,
                    mutation=f"{antibody_structure.sequence[position]}{position}{aa}"
                )

                if predicted_ddg < -0.5:  # 有利变化(负值越大越好)
                    variants.append({
                        'position': position,
                        'original': antibody_structure.sequence[position],
                        'mutant': aa,
                        'predicted_ddg': predicted_ddg,
                        'predicted_kd_fold': calculate_kd_change(predicted_ddg)
                    })

    # 按预测提升效果排序
    return sorted(variants, key=lambda x: x['predicted_ddg'])

4.2 CDR Optimization Strategies

4.2 CDR优化策略

python
def cdr_optimization_strategies(cdr_sequence, cdr_name):
    """Identify CDR optimization strategies based on sequence and structure."""

    strategies = []

    # Strategy 1: Extend CDR for increased contact area
    if len(cdr_sequence) < 12 and cdr_name == 'CDR-H3':
        strategies.append({
            'strategy': 'CDR-H3 extension',
            'rationale': 'Add 1-2 residues to increase contact surface',
            'expected_impact': '+2-5x affinity improvement',
            'examples': ['Extension with Gly-Tyr', 'Extension with Ser-Asp']
        })

    # Strategy 2: Tyrosine enrichment
    tyr_count = cdr_sequence.count('Y')
    if tyr_count < 2:
        strategies.append({
            'strategy': 'Tyrosine enrichment',
            'rationale': 'Tyr provides pi-stacking and H-bonds',
            'expected_impact': '+2-3x affinity improvement',
            'targets': suggest_tyr_positions(cdr_sequence)
        })

    # Strategy 3: Charged residue optimization
    if 'PD' in cdr_sequence or 'EP' in cdr_sequence:
        strategies.append({
            'strategy': 'Salt bridge formation',
            'rationale': 'Add charged residues for electrostatic interactions',
            'expected_impact': '+1-2x affinity and pH sensitivity',
            'targets': identify_salt_bridge_opportunities(cdr_sequence)
        })

    return strategies
python
def cdr_optimization_strategies(cdr_sequence, cdr_name):
    """基于序列和结构识别CDR优化策略。"""

    strategies = []

    # 策略1: 延长CDR以增加接触面积
    if len(cdr_sequence) < 12 and cdr_name == 'CDR-H3':
        strategies.append({
            'strategy': 'CDR-H3延长',
            'rationale': '添加1-2个残基以增加结合表面积',
            'expected_impact': '+2-5倍亲和力提升',
            'examples': ['添加Gly-Tyr', '添加Ser-Asp']
        })

    # 策略2: 酪氨酸富集
    tyr_count = cdr_sequence.count('Y')
    if tyr_count < 2:
        strategies.append({
            'strategy': '酪氨酸富集',
            'rationale': '酪氨酸可提供π-堆积和氢键相互作用',
            'expected_impact': '+2-3倍亲和力提升',
            'targets': suggest_tyr_positions(cdr_sequence)
        })

    # 策略3: 带电残基优化
    if 'PD' in cdr_sequence or 'EP' in cdr_sequence:
        strategies.append({
            'strategy': '盐桥形成',
            'rationale': '添加带电残基以形成静电相互作用',
            'expected_impact': '+1-2倍亲和力提升及pH敏感性',
            'targets': identify_salt_bridge_opportunities(cdr_sequence)
        })

    return strategies

4.3 Output for Report

4.3 报告输出内容

markdown
undefined
markdown
undefined

4. Affinity Optimization

4. 亲和力优化

4.1 Current Affinity Assessment

4.1 当前亲和力评估

PropertyValueMethod
Predicted KD5.2 nMStructure-based prediction
Buried surface area820 ŲAlphaFold model
Interface hotspots6 residuesEnergy decomposition
Target: Single-digit nM affinity (KD < 5 nM)
属性数值方法
预测KD值5.2 nM基于结构的预测
掩埋表面积820 ŲAlphaFold模型
界面热点残基6个能量分解分析
目标: 纳摩尔级亲和力(KD < 5 nM)

4.2 Proposed Affinity Mutations

4.2 建议的亲和力突变

High-Priority Mutations (predicted >2x improvement):
PositionOriginalMutantRegionPredicted ΔΔGKD Fold ImprovementRationale
H100aSYCDR-H3-1.2 kcal/mol7.4xPi-stacking with target Phe
H52IWCDR-H2-0.9 kcal/mol4.8xIncreased hydrophobic contact
L91QECDR-L3-0.7 kcal/mol3.3xSalt bridge with target Arg
H58GSCDR-H2-0.6 kcal/mol2.7xH-bond to target backbone
Medium-Priority Mutations (predicted 1.5-2x improvement):
PositionOriginalMutantRegionPredicted ΔΔGKD Fold ImprovementRationale
H33YFCDR-H1-0.5 kcal/mol2.3xOptimize stacking geometry
L50ATCDR-L2-0.4 kcal/mol2.0xAdditional H-bond
高优先级突变(预测提升>2倍):
位置原始残基突变残基区域预测ΔΔGKD值提升倍数依据
H100aSYCDR-H3-1.2 kcal/mol7.4倍与靶点苯丙氨酸形成π-堆积
H52IWCDR-H2-0.9 kcal/mol4.8倍增加疏水相互作用
L91QECDR-L3-0.7 kcal/mol3.3倍与靶点精氨酸形成盐桥
H58GSCDR-H2-0.6 kcal/mol2.7倍与靶点主链形成氢键
中优先级突变(预测提升1.5-2倍):
位置原始残基突变残基区域预测ΔΔGKD值提升倍数依据
H33YFCDR-H1-0.5 kcal/mol2.3倍优化堆积几何结构
L50ATCDR-L2-0.4 kcal/mol2.0倍增加氢键相互作用

4.3 Combination Strategy

4.3 组合策略

Recommended Testing Order:
  1. Single mutants: H100aY, H52W, L91E (test individually)
  2. Double mutants: H100aY+H52W, H100aY+L91E (best combinations)
  3. Triple mutant: H100aY+H52W+L91E (if additivity observed)
Expected Outcome:
  • Single mutants: KD 1.5-2.5 nM (3-7x improvement)
  • Best double mutant: KD 0.7-1.2 nM (7-15x improvement)
  • Triple mutant: KD 0.3-0.6 nM (15-30x improvement) if additive
建议测试顺序:
  1. 单点突变: H100aY、H52W、L91E(单独测试)
  2. 双点突变: H100aY+H52W、H100aY+L91E(最优组合)
  3. 三点突变: H100aY+H52W+L91E(如观察到叠加效应)
预期结果:
  • 单点突变: KD值1.5-2.5 nM(3-7倍提升)
  • 最优双点突变: KD值0.7-1.2 nM(7-15倍提升)
  • 三点突变: 如叠加效应存在,KD值0.3-0.6 nM(15-30倍提升)

4.4 CDR Optimization Strategies

4.4 CDR优化策略

Strategy 1: CDR-H3 Extension
  • Current length: 14 aa
  • Proposed: Add Gly-Tyr at C-terminus (16 aa total)
  • Rationale: Fill gap in binding interface, Tyr provides pi-stacking
  • Expected impact: +2-3x affinity
Strategy 2: Tyrosine Enrichment
  • Current Tyr count: 3 in CDRs
  • Target positions: H33, H52a, L96
  • Rationale: Tyr provides both hydrophobic and H-bond contacts
  • Expected impact: +2-4x affinity
Strategy 3: pH-Dependent Binding (Optional)
  • For tumor-selective uptake
  • Add His residues at interface: H100a, L91
  • pKa ~6.0: Bind at pH 7.4, release at pH 6.0
  • Expected impact: Tumor selectivity, faster recycling
Source: In silico modeling, structural analysis

---
策略1: CDR-H3延长
  • 当前长度: 14 aa
  • 建议: 在C末端添加Gly-Tyr(总长度16 aa)
  • 依据: 填补结合界面间隙,酪氨酸提供π-堆积作用
  • 预期影响: +2-3倍亲和力提升
策略2: 酪氨酸富集
  • 当前CDR区酪氨酸数量: 3个
  • 目标位置: H33、H52a、L96
  • 依据: 酪氨酸可同时提供疏水和氢键相互作用
  • 预期影响: +2-4倍亲和力提升
策略3: pH依赖性结合(可选)
  • 用于肿瘤选择性摄取
  • 在结合界面添加组氨酸残基: H100a、L91
  • pKa ~6.0: 在pH7.4下结合,pH6.0下解离
  • 预期影响: 肿瘤选择性,循环半衰期延长
来源: 计算建模, 结构分析

---

Phase 5: Developability Assessment

阶段5: 成药性评估

5.1 Aggregation Propensity

5.1 聚集倾向性

python
def assess_aggregation(sequence):
    """Comprehensive aggregation risk assessment."""

    # Identify aggregation-prone regions (APR)
    aprs = find_aggregation_motifs(sequence)

    # Hydrophobic patches on surface
    hydrophobic_patches = identify_surface_hydrophobic(sequence)

    # Charge patches (extreme pI regions)
    charge_patches = identify_charge_clusters(sequence)

    # Sequence-based prediction scores
    tango_score = predict_tango_score(sequence)  # Beta-aggregation
    aggrescan_score = predict_aggrescan(sequence)  # General aggregation

    # Isoelectric point
    pi = calculate_isoelectric_point(sequence)

    return {
        'apr_count': len(aprs),
        'apr_regions': aprs,
        'hydrophobic_patches': hydrophobic_patches,
        'charge_patches': charge_patches,
        'tango_score': tango_score,
        'aggrescan_score': aggrescan_score,
        'pi': pi,
        'overall_risk': categorize_risk(tango_score, aggrescan_score, len(aprs))
    }
python
def assess_aggregation(sequence):
    """综合评估聚集风险。"""

    # 识别聚集倾向性区域(APR)
    aprs = find_aggregation_motifs(sequence)

    # 表面疏水斑块
    hydrophobic_patches = identify_surface_hydrophobic(sequence)

    # 电荷斑块(极端pI区域)
    charge_patches = identify_charge_clusters(sequence)

    # 基于序列的预测评分
    tango_score = predict_tango_score(sequence)  # β-聚集倾向性
    aggrescan_score = predict_aggrescan(sequence)  # 整体聚集倾向性

    # 等电点
    pi = calculate_isoelectric_point(sequence)

    return {
        'apr_count': len(aprs),
        'apr_regions': aprs,
        'hydrophobic_patches': hydrophobic_patches,
        'charge_patches': charge_patches,
        'tango_score': tango_score,
        'aggrescan_score': aggrescan_score,
        'pi': pi,
        'overall_risk': categorize_risk(tango_score, aggrescan_score, len(aprs))
    }

5.2 PTM Site Identification

5.2 PTM位点识别

python
def identify_ptm_sites(sequence):
    """Identify post-translational modification liability sites."""

    ptm_sites = {
        'deamidation': [],
        'isomerization': [],
        'oxidation': [],
        'glycosylation': []
    }

    # Deamidation: Asn followed by Gly or Ser (NG, NS motifs)
    for i, aa in enumerate(sequence[:-1]):
        if aa == 'N' and sequence[i+1] in ['G', 'S']:
            ptm_sites['deamidation'].append({
                'position': i,
                'motif': sequence[i:i+2],
                'risk': 'High' if sequence[i+1] == 'G' else 'Medium',
                'region': identify_region(i)
            })

    # Isomerization: Asp followed by Gly or Ser (DG, DS motifs)
    for i, aa in enumerate(sequence[:-1]):
        if aa == 'D' and sequence[i+1] in ['G', 'S']:
            ptm_sites['isomerization'].append({
                'position': i,
                'motif': sequence[i:i+2],
                'risk': 'High',
                'region': identify_region(i)
            })

    # Oxidation: Met and Trp residues
    for i, aa in enumerate(sequence):
        if aa in ['M', 'W']:
            ptm_sites['oxidation'].append({
                'position': i,
                'residue': aa,
                'risk': 'Medium',
                'region': identify_region(i)
            })

    # N-glycosylation: N-X-S/T motif (X != P)
    for i in range(len(sequence)-2):
        if sequence[i] == 'N' and sequence[i+1] != 'P' and sequence[i+2] in ['S', 'T']:
            ptm_sites['glycosylation'].append({
                'position': i,
                'motif': sequence[i:i+3],
                'region': identify_region(i)
            })

    return ptm_sites
python
def identify_ptm_sites(sequence):
    """识别翻译后修饰(PTM)风险位点。"""

    ptm_sites = {
        '脱酰胺': [],
        '异构化': [],
        '氧化': [],
        '糖基化': []
    }

    # 脱酰胺: 天冬酰胺后接甘氨酸或丝氨酸(NG、NS基序)
    for i, aa in enumerate(sequence[:-1]):
        if aa == 'N' and sequence[i+1] in ['G', 'S']:
            ptm_sites['脱酰胺'].append({
                'position': i,
                'motif': sequence[i:i+2],
                'risk': '高' if sequence[i+1] == 'G' else '中',
                'region': identify_region(i)
            })

    # 异构化: 天冬氨酸后接甘氨酸或丝氨酸(DG、DS基序)
    for i, aa in enumerate(sequence[:-1]):
        if aa == 'D' and sequence[i+1] in ['G', 'S']:
            ptm_sites['异构化'].append({
                'position': i,
                'motif': sequence[i:i+2],
                'risk': '高',
                'region': identify_region(i)
            })

    # 氧化: 甲硫氨酸和色氨酸残基
    for i, aa in enumerate(sequence):
        if aa in ['M', 'W']:
            ptm_sites['氧化'].append({
                'position': i,
                'residue': aa,
                'risk': '中',
                'region': identify_region(i)
            })

    # N-糖基化: N-X-S/T基序(X≠P)
    for i in range(len(sequence)-2):
        if sequence[i] == 'N' and sequence[i+1] != 'P' and sequence[i+2] in ['S', 'T']:
            ptm_sites['糖基化'].append({
                'position': i,
                'motif': sequence[i:i+3],
                'region': identify_region(i)
            })

    return ptm_sites

5.3 Developability Scoring

5.3 成药性评分

python
def calculate_developability_score(sequence, structure):
    """Calculate comprehensive developability score (0-100)."""

    # Component scores
    aggregation = assess_aggregation(sequence)
    ptm = identify_ptm_sites(sequence)
    stability = predict_thermal_stability(structure)
    expression = predict_expression_level(sequence)
    solubility = predict_solubility(sequence)

    # Scoring rubric (0-100 for each)
    scores = {
        'aggregation': score_aggregation(aggregation),  # 100 = low risk
        'ptm_liability': score_ptm_risk(ptm),  # 100 = no PTM sites
        'stability': score_stability(stability),  # 100 = Tm > 70°C
        'expression': score_expression(expression),  # 100 = >1 g/L
        'solubility': score_solubility(solubility)  # 100 = >100 mg/mL
    }

    # Weighted average
    weights = {
        'aggregation': 0.30,  # Most critical
        'ptm_liability': 0.25,
        'stability': 0.20,
        'expression': 0.15,
        'solubility': 0.10
    }

    overall = sum(scores[k] * weights[k] for k in scores.keys())

    return {
        'component_scores': scores,
        'overall_score': overall,
        'tier': categorize_developability(overall)
    }
python
def calculate_developability_score(sequence, structure):
    """计算综合成药性评分(0-100)。"""

    # 各维度评分
    aggregation = assess_aggregation(sequence)
    ptm = identify_ptm_sites(sequence)
    stability = predict_thermal_stability(structure)
    expression = predict_expression_level(sequence)
    solubility = predict_solubility(sequence)

    # 评分标准(各维度0-100分)
    scores = {
        'aggregation': score_aggregation(aggregation),  # 100=低风险
        'ptm_liability': score_ptm_risk(ptm),  # 100=无PTM风险位点
        'stability': score_stability(stability),  # 100=Tm>70°C
        'expression': score_expression(expression),  # 100=>1g/L
        'solubility': score_solubility(solubility)  # 100=>100mg/mL
    }

    # 加权平均
    weights = {
        'aggregation': 0.30,  # 最关键
        'ptm_liability': 0.25,
        'stability': 0.20,
        'expression': 0.15,
        'solubility': 0.10
    }

    overall = sum(scores[k] * weights[k] for k in scores.keys())

    return {
        'component_scores': scores,
        'overall_score': overall,
        'tier': categorize_developability(overall)
    }

5.4 Output for Report

5.4 报告输出内容

markdown
undefined
markdown
undefined

5. Developability Assessment

5. 成药性评估

5.1 Overall Developability Score

5.1 综合成药性评分

VariantAggregationPTM LiabilityStabilityExpressionSolubilityOverallTier
Original (Mouse)584572657062T3
VH_Humanized_v1725575787571T2
VH_Humanized_v2685874757369T2
Affinity_opt857278808279T1
Scoring: 0-100 scale (higher is better), Tiers: T1 (>75), T2 (60-75), T3 (<60)
变体聚集风险PTM风险稳定性表达量溶解度综合评分等级
原始鼠源序列584572657062T3
VH_Humanized_v1725575787571T2
VH_Humanized_v2685874757369T2
亲和力优化变体857278808279T1
评分标准: 0-100分(越高越好),等级划分: T1(>75), T2(60-75), T3(<60)

5.2 Aggregation Analysis

5.2 聚集分析

Aggregation-Prone Regions (APR) in VH:
PositionSequenceRegionTANGO ScoreRiskRecommendation
85-92STSTAYMELFR342MediumConsider T86S mutation
108-112DDGSYCDR-H328LowMonitor in formulation
Overall Aggregation Risk:
  • VH: Low (TANGO: 15, AGGRESCAN: -12)
  • VL: Very Low (TANGO: 8, AGGRESCAN: -18)
  • pI: VH 7.2, VL 5.8 (favorable for purification)
Recommendations:
  • Formulate at pH 6.0-6.5 (below pI of VH)
  • Add arginine-glutamate (20-50 mM) to reduce aggregation
  • Target concentration: >100 mg/mL achievable
VH链中的聚集倾向性区域(APR):
位置序列区域TANGO评分风险建议
85-92STSTAYMELFR342考虑T86S突变
108-112DDGSYCDR-H328制剂中监测
整体聚集风险:
  • VH链: 低(TANGO:15, AGGRESCAN:-12)
  • VL链: 极低(TANGO:8, AGGRESCAN:-18)
  • pI: VH7.2, VL5.8(利于纯化)
建议:
  • 在pH6.0-6.5条件下制剂(低于VH链pI)
  • 添加20-50 mM精氨酸-谷氨酸以减少聚集
  • 可实现>100 mg/mL的目标浓度

5.3 PTM Liability Sites

5.3 PTM风险位点

High-Risk PTM Sites (require mitigation):
PositionMotifPTM TypeRiskRegionMitigation Strategy
H54-55NGDeamidationHighCDR-H2Mutate to NQ or QG
H84-85DSIsomerizationHighFR3Mutate to ES or DA
L28MOxidationMediumCDR-L1Mutate to Leu or Ile
Medium-Risk Sites:
  • H89: Trp (oxidation) - Monitor but likely stable in framework
  • L97: Asn (deamidation, NS motif) - Low risk in CDR-L3
Mitigation Priority:
  1. H54-55 (NG → NQ): Removes high-risk deamidation, retains H-bond capability
  2. H84-85 (DS → ES): Removes isomerization, maintains charge
  3. L28 (M → L): Reduces oxidation risk, maintains hydrophobicity
Expected Impact: Mitigation improves PTM score from 72 → 92
高风险PTM位点(需缓解):
位置基序PTM类型风险区域缓解策略
H54-55NG脱酰胺CDR-H2突变为NQ或QG
H84-85DS异构化FR3突变为ES或DA
L28M氧化CDR-L1突变为亮氨酸或异亮氨酸
中风险位点:
  • H89: 色氨酸(氧化)- 监测即可,框架区中通常稳定
  • L97: 天冬酰胺(脱酰胺,NS基序)- CDR-L3中风险较低
缓解优先级:
  1. H54-55(NG→NQ): 消除高风险脱酰胺位点,保留氢键能力
  2. H84-85(DS→ES): 消除异构化风险,维持电荷
  3. L28(M→L): 降低氧化风险,维持疏水性
预期影响: 缓解后PTM评分从72提升至92

5.4 Stability Predictions

5.4 稳定性预测

Thermal Stability:
VariantPredicted Tm (°C)ΔTm vs OriginalAggregation TonsetStability Tier
Original68-62°CT3 (Marginal)
Humanized_v271+3°C64°CT2 (Good)
Affinity_opt73+5°C67°CT2 (Good)
PTM_mitigated74+6°C69°CT1 (Excellent)
Target: Tm >70°C, Tonset >65°C for long-term stability
Stability Optimization:
  • Framework humanization improved Tm by +3°C
  • Removal of destabilizing motifs: +2°C
  • Further optimization possible: Proline introduction in loops
热稳定性:
变体预测Tm(°C)与原始序列的ΔTm聚集起始温度稳定性等级
原始序列68-62°CT3(边缘水平)
人源化v271+3°C64°CT2(良好)
亲和力优化变体73+5°C67°CT2(良好)
PTM缓解后变体74+6°C69°CT1(优秀)
目标: Tm>70°C,聚集起始温度>65°C以保证长期稳定性
稳定性优化:
  • 框架区人源化使Tm提升+3°C
  • 去除不稳定基序使Tm提升+2°C
  • 进一步优化方向: 在环区引入脯氨酸

5.5 Expression & Manufacturing

5.5 表达与生产

Expression Prediction (CHO cells):
VariantPredicted Titer (g/L)Soluble FractionHis-tag PurificationOverall
Original1.275%GoodT2
Humanized_v21.885%ExcellentT1
Affinity_opt2.188%ExcellentT1
Manufacturing Considerations:
  • No unusual codons → Good for CHO expression
  • No free cysteines → No misfolding risk
  • Neutral pI → Easy purification by ion exchange
  • Low aggregation → High formulation concentration possible
Predicted Manufacturing Profile:
  • Expression: 2.0 g/L (CHO fed-batch)
  • Purification yield: 75-80%
  • Final formulation: >150 mg/mL achievable
  • Shelf life: >2 years at 4°C (estimated)
Source: In silico predictions, sequence analysis

---
表达预测(CHO细胞):
变体预测滴度(g/L)可溶性比例Protein A纯化效果综合等级
原始序列1.275%良好T2
人源化v21.885%优秀T1
亲和力优化变体2.188%优秀T1
生产考量:
  • 无稀有密码子 → 适合CHO表达
  • 无游离半胱氨酸 → 无错误折叠风险
  • 中性pI → 易于通过离子交换纯化
  • 低聚集性 → 可实现高制剂浓度
预测生产概况:
  • 表达量: 2.0 g/L(CHO流加培养)
  • 纯化收率: 75-80%
  • 最终制剂浓度: 可实现>150 mg/mL
  • 保质期: 4°C下>2年(预估)
来源: 计算预测, 序列分析

---

Phase 6: Immunogenicity Prediction

阶段6: 免疫原性预测

6.1 T-Cell Epitope Prediction

6.1 T细胞表位预测

python
def predict_tcell_epitopes(tu, sequence):
    """Predict T-cell epitopes using IEDB tools."""

    # MHC-II binding prediction (immunogenicity risk)
    # Query IEDB for predicted epitopes
    predicted_epitopes = []

    # Scan sequence with 9-mer sliding window
    for i in range(len(sequence) - 8):
        peptide = sequence[i:i+9]

        # Search IEDB for similar epitopes
        iedb_results = tu.tools.iedb_search_epitopes(
            sequence_contains=peptide[:5],  # Core sequence
            limit=10
        )

        # If found in IEDB → higher risk
        if len(iedb_results) > 0:
            predicted_epitopes.append({
                'position': i,
                'peptide': peptide,
                'risk': 'High',
                'evidence': f"{len(iedb_results)} similar epitopes in IEDB"
            })

    # Score overall immunogenicity risk
    risk_score = calculate_immunogenicity_risk(predicted_epitopes, sequence)

    return {
        'epitope_count': len(predicted_epitopes),
        'high_risk_epitopes': [e for e in predicted_epitopes if e['risk'] == 'High'],
        'risk_score': risk_score,
        'recommendation': recommend_deimmunization(predicted_epitopes)
    }
python
def predict_tcell_epitopes(tu, sequence):
    """利用IEDB工具预测T细胞表位。"""

    # MHC-II结合预测(免疫原性风险)
    # 查询IEDB获取预测表位
    predicted_epitopes = []

    # 用9肽滑动窗口扫描序列
    for i in range(len(sequence) - 8):
        peptide = sequence[i:i+9]

        # 在IEDB中搜索相似表位
        iedb_results = tu.tools.iedb_search_epitopes(
            sequence_contains=peptide[:5],  # 核心序列
            limit=10
        )

        # 如果在IEDB中存在 → 风险更高
        if len(iedb_results) > 0:
            predicted_epitopes.append({
                'position': i,
                'peptide': peptide,
                'risk': '高',
                'evidence': f"IEDB中存在{len(iedb_results)}个相似表位"
            })

    # 计算整体免疫原性风险评分
    risk_score = calculate_immunogenicity_risk(predicted_epitopes, sequence)

    return {
        'epitope_count': len(predicted_epitopes),
        'high_risk_epitopes': [e for e in predicted_epitopes if e['risk'] == '高'],
        'risk_score': risk_score,
        'recommendation': recommend_deimmunization(predicted_epitopes)
    }

6.2 Immunogenicity Risk Scoring

6.2 免疫原性风险评分

python
def calculate_immunogenicity_risk(epitopes, sequence):
    """Calculate comprehensive immunogenicity risk score."""

    # Component 1: T-cell epitope count (IEDB-based)
    tcell_score = len(epitopes) * 10  # Each epitope adds 10 points

    # Component 2: Non-human residues in framework
    non_human_residues = count_non_human_residues(sequence)
    non_human_score = non_human_residues * 5

    # Component 3: Aggregation-related immunogenicity
    aggregation_score = assess_aggregation(sequence)['overall_risk'] * 20

    # Total risk (0-100, lower is better)
    total_risk = min(100, tcell_score + non_human_score + aggregation_score)

    return {
        'tcell_risk': tcell_score,
        'non_human_risk': non_human_score,
        'aggregation_risk': aggregation_score,
        'total_risk': total_risk,
        'category': 'Low' if total_risk < 30 else 'Medium' if total_risk < 60 else 'High'
    }
python
def calculate_immunogenicity_risk(epitopes, sequence):
    """计算综合免疫原性风险评分。"""

    # 维度1: T细胞表位数量(基于IEDB)
    tcell_score = len(epitopes) * 10  # 每个表位加10分

    # 维度2: 框架区中的非人源残基数量
    non_human_residues = count_non_human_residues(sequence)
    non_human_score = non_human_residues * 5

    # 维度3: 聚集相关免疫原性
    aggregation_score = assess_aggregation(sequence)['overall_risk'] * 20

    # 总风险(0-100,越低越好)
    total_risk = min(100, tcell_score + non_human_score + aggregation_score)

    return {
        'tcell_risk': tcell_score,
        'non_human_risk': non_human_score,
        'aggregation_risk': aggregation_score,
        'total_risk': total_risk,
        'category': '低' if total_risk < 30 else '中' if total_risk < 60 else '高'
    }

6.3 Output for Report

6.3 报告输出内容

markdown
undefined
markdown
undefined

6. Immunogenicity Prediction

6. 免疫原性预测

6.1 T-Cell Epitope Analysis

6.1 T细胞表位分析

Predicted MHC-II Binding Epitopes (IEDB):
PositionPeptideMHC AllelesIEDB MatchesRisk LevelRegion
VH 48-56QGLEWMGGIHLA-DR1, DR43MediumFR2
VH 78-86TDTSTSTAHLA-DR15HighFR3 (mouse residues)
VL 52-60LLIYSASSLHLA-DR1, DR152MediumFR2
High-Risk Epitope Details:
  • VH 78-86 (TDTSTSTA): Contains mouse-derived residues T84, S85
    • Found in 5 immunogenic peptides in IEDB
    • Recommendation: Backmutate to human consensus (TSTSSAYL)
预测的MHC-II结合表位(IEDB):
位置肽段MHC等位基因IEDB匹配数风险等级区域
VH48-56QGLEWMGGIHLA-DR1、DR43FR2
VH78-86TDTSTSTAHLA-DR15FR3(鼠源残基)
VL52-60LLIYSASSLHLA-DR1、DR152FR2
高风险表位详情:
  • VH78-86(TDTSTSTA): 包含鼠源残基T84、S85
    • 在IEDB中存在5个免疫原性相似肽段
    • 建议: 回复突变为人类共识序列(TSTSSAYL)

6.2 Immunogenicity Risk Score

6.2 免疫原性风险评分

VariantT-Cell EpitopesNon-Human ResiduesAggregation RiskTotal RiskCategory
Original (Mouse)1238High (40)118High
VH_Humanized_v1513Medium (20)60Medium
VH_Humanized_v2415Medium (18)53Medium
Deimmunized210Low (12)32Low
Risk Scoring: 0-100 (lower is better)
  • Low risk: <30 (clinical candidate ready)
  • Medium risk: 30-60 (acceptable with monitoring)
  • High risk: >60 (requires optimization)
变体T细胞表位数量非人源残基数量聚集风险总风险评分类别
原始鼠源序列1238高(40)118
VH_Humanized_v1513中(20)60
VH_Humanized_v2415中(18)53
去免疫原化变体210低(12)32
风险评分标准: 0-100分(越低越好)
  • 低风险: <30(可作为临床候选药物)
  • 中风险: 30-60(可接受,需监测)
  • 高风险: >60(需优化)

6.3 Deimmunization Strategy

6.3 去免疫原化策略

Recommended Mutations (to achieve low risk):
PositionOriginalMutantRegionRationaleImpact
VH 78TAFR3Human consensus, removes epitope-15 risk
VH 84TSFR3Human consensus, removes epitope-12 risk
VL 55SAFR2Removes MHC-II binding-8 risk
Expected Outcome:
  • Deimmunization reduces risk score: 53 → 32 (Low)
  • T-cell epitopes reduced: 4 → 2
  • Maintains CDR sequences (no affinity impact)
建议突变(实现低风险):
位置原始残基突变残基区域依据影响
VH78TAFR3人类共识序列,消除表位风险降低15分
VH84TSFR3人类共识序列,消除表位风险降低12分
VL55SAFR2消除MHC-II结合风险降低8分
预期结果:
  • 去免疫原化使风险评分从53降至32(低风险)
  • T细胞表位数量从4个降至2个
  • 保留CDR序列(无亲和力损失)

6.4 Clinical Precedent Comparison

6.4 临床先例对比

Approved Antibodies - Immunogenicity Rates:
AntibodyTarget% ADA (Anti-Drug Antibodies)Humanization
AtezolizumabPD-L130%Fully human
DurvalumabPD-L16%Fully human
TrastuzumabHER213%Humanized (93%)
RituximabCD2011%Chimeric (66%)
Our Candidate:
  • Humanization: 85-87% (similar to trastuzumab)
  • Predicted ADA risk: 10-15% (after deimmunization)
  • Acceptable for clinical development
Source: IEDB, TheraSAbDab, clinical trial data

---
已获批抗体的免疫原性发生率:
抗体靶点%ADA(抗药物抗体)人源化程度
AtezolizumabPD-L130%全人源
DurvalumabPD-L16%全人源
TrastuzumabHER213%人源化(93%)
RituximabCD2011%嵌合型(66%)
候选抗体:
  • 人源化程度: 85-87%(与Trastuzumab相似)
  • 预测ADA风险: 10-15%(去免疫原化后)
  • 符合临床开发要求
来源: IEDB, TheraSAbDab, 临床试验数据

---

Phase 7: Manufacturing Feasibility

阶段7: 生产可行性分析

7.1 Expression Optimization

7.1 表达优化

python
def assess_manufacturing_feasibility(sequence):
    """Assess manufacturing and CMC feasibility."""

    # Codon optimization for CHO
    cho_optimized = optimize_codons(sequence, host='CHO')
    rare_codons = count_rare_codons(sequence, host='CHO')

    # Signal peptide design
    signal_peptide = design_signal_peptide(sequence)

    # Purification considerations
    purification = {
        'protein_a_binding': check_protein_a_binding(sequence),
        'ion_exchange': suggest_ion_exchange_conditions(sequence),
        'hydrophobic': suggest_hic_conditions(sequence)
    }

    # Formulation
    formulation = {
        'target_concentration': predict_max_concentration(sequence),
        'buffer': suggest_buffer_conditions(sequence),
        'stabilizers': suggest_stabilizers(sequence),
        'shelf_life': predict_shelf_life(sequence)
    }

    return {
        'expression': {'cho_optimized': cho_optimized, 'rare_codons': rare_codons},
        'purification': purification,
        'formulation': formulation
    }
python
def assess_manufacturing_feasibility(sequence):
    """评估生产及CMC可行性。"""

    # CHO细胞密码子优化
    cho_optimized = optimize_codons(sequence, host='CHO')
    rare_codons = count_rare_codons(sequence, host='CHO')

    # 信号肽设计
    signal_peptide = design_signal_peptide(sequence)

    # 纯化考量
    purification = {
        'protein_a_binding': check_protein_a_binding(sequence),
        'ion_exchange': suggest_ion_exchange_conditions(sequence),
        'hydrophobic': suggest_hic_conditions(sequence)
    }

    # 制剂
    formulation = {
        'target_concentration': predict_max_concentration(sequence),
        'buffer': suggest_buffer_conditions(sequence),
        'stabilizers': suggest_stabilizers(sequence),
        'shelf_life': predict_shelf_life(sequence)
    }

    return {
        'expression': {'cho_optimized': cho_optimized, 'rare_codons': rare_codons},
        'purification': purification,
        'formulation': formulation
    }

7.2 Output for Report

7.2 报告输出内容

markdown
undefined
markdown
undefined

7. Manufacturing Feasibility

7. 生产可行性分析

7.1 Expression Assessment

7.1 表达评估

Expression System: CHO (Chinese Hamster Ovary) cells
ParameterAssessmentDetails
Codon optimizationGood5% rare codons (CHO)
Signal peptideNative IgG leaderMETDTLLLWVLLLWVPGSTG
Predicted titer2.0 g/LFed-batch, 14-day culture
Soluble fraction88%High solubility predicted
Recommendations:
  • Use standard CHO expression system (CHO-K1 or CHO-S)
  • Express as full IgG1 (not Fab) for Protein A purification
  • Standard fed-batch process (no special requirements)
表达系统: CHO(中国仓鼠卵巢)细胞
参数评估结果详情
密码子优化良好CHO细胞中稀有密码子占比5%
信号肽天然IgG前导肽METDTLLLWVLLLWVPGSTG
预测滴度2.0 g/L流加培养,14天周期
可溶性比例88%预测溶解度高
建议:
  • 使用标准CHO表达系统(CHO-K1或CHO-S)
  • 表达为完整IgG1(而非Fab)以利用Protein A纯化
  • 采用标准流加培养工艺(无特殊要求)

7.2 Purification Strategy

7.2 纯化策略

Recommended 3-Step Purification:
StepMethodPurposeExpected YieldPurity
1. CaptureProtein A affinityIgG capture>95%>90%
2. PolishingCation exchange (SP)Aggregate/variant removal>90%>98%
3. ViralNanofiltration (20 nm)Viral clearance>95%>99%
Overall Process Yield: 75-80% (from clarified harvest to final product)
Purification Conditions:
  • Protein A: Standard pH 3.5 elution
  • Cation exchange: pH 5.0-5.5 binding, salt gradient elution
  • No special requirements (standard IgG process)
建议三步纯化流程:
步骤方法目的预期收率纯度
1. 捕获Protein A亲和层析IgG捕获>95%>90%
2. 精纯阳离子交换(SP)去除聚集体/变体>90%>98%
3. 病毒去除纳米过滤(20 nm)病毒清除>95%>99%
整体工艺收率: 75-80%(从澄清收获液到最终产品)
纯化条件:
  • Protein A: 标准pH3.5洗脱
  • 阳离子交换: pH5.0-5.5结合,盐梯度洗脱
  • 无特殊要求(标准IgG工艺)

7.3 Formulation Development

7.3 制剂开发

Recommended Formulation:
ComponentConcentrationPurpose
Antibody150 mg/mLHigh concentration for SC delivery
Buffer20 mM Histidine-HClpH buffering, stability
pH6.0Minimizes aggregation (below pI)
Stabilizer0.02% Polysorbate 80Reduces surface adsorption
Tonicity240 mM SucroseIsotonic, cryoprotectant
Formulation Characteristics:
  • Viscosity: <15 cP (suitable for SC injection)
  • Osmolality: 300 mOsm/kg (isotonic)
  • Stability: >2 years at 2-8°C (predicted)
  • Freeze/thaw: Stable for 5 cycles
Alternative Formulations (if needed):
  • Lower concentration (100 mg/mL) for IV delivery
  • Add arginine-glutamate (50 mM) if aggregation observed
  • Trehalose (5%) as alternative stabilizer
建议制剂配方:
组分浓度用途
抗体150 mg/mL高浓度用于皮下注射
缓冲液20 mM组氨酸-HClpH缓冲,维持稳定性
pH值6.0最小化聚集(低于pI)
稳定剂0.02%聚山梨酯80减少表面吸附
渗透压调节剂240 mM蔗糖等渗,冷冻保护剂
制剂特性:
  • 粘度: <15 cP(适合皮下注射)
  • 渗透压: 300 mOsm/kg(等渗)
  • 稳定性: 2-8°C下>2年(预测)
  • 冻融稳定性: 可耐受5次冻融循环
备选制剂(如需):
  • 低浓度(100 mg/mL)用于静脉注射
  • 若出现聚集,添加50 mM精氨酸-谷氨酸
  • 以5%海藻糖作为备选稳定剂

7.4 Analytical Characterization

7.4 分析表征

Required Assays (ICH guidelines):
AssayPurposeSpecification
SEC-MALSMonomer content>95% monomer
CEXCharge variantsMain peak >70%
CE-SDSPurity (reduced/non-reduced)>95% main peak
IEF/cIEFIsoelectric pointpI 7.0-7.5
SPR/ELISABinding affinityKD <5 nM
DSFThermal stabilityTm >65°C
Cell-basedBioactivityEC50 <10 nM
必需检测项目(ICH指南):
检测项目目的质量标准
SEC-MALS单体含量>95%单体
CEX电荷变体主峰占比>70%
CE-SDS纯度(还原/非还原)主峰占比>95%
IEF/cIEF等电点pI7.0-7.5
SPR/ELISA结合亲和力KD<5 nM
DSF热稳定性Tm>65°C
细胞水平检测生物活性EC50<10 nM

7.5 CMC Timeline & Costs

7.5 CMC timeline & Costs

Estimated Development Timeline:
PhaseDurationActivitiesCost Estimate
Cell line development4-6 monthsTransfection, selection, cloning$150K
Process development6-9 monthsOptimization, scale-up$300K
Analytical development3-6 monthsMethod development, validation$200K
GMP manufacturing9-12 monthsTech transfer, clinical batches$1-2M
Total to IND18-24 months-$1.65-2.65M
Manufacturing Scale:
  • Phase 1: 5-10g (small scale, 50L bioreactor)
  • Phase 2: 50-100g (pilot scale, 200L)
  • Phase 3: 500g-1kg (commercial scale, 2000L)
预估开发周期:
阶段时长活动成本预估
细胞株开发4-6个月转染、筛选、克隆$150K
工艺开发6-9个月优化、放大$300K
分析方法开发3-6个月方法开发、验证$200K
GMP生产9-12个月技术转移、临床批次生产$1-2M
IND申报前总时长18-24个月-$1.65-2.65M
生产规模:
  • I期临床: 5-10g(小试规模,50L生物反应器)
  • II期临床: 50-100g(中试规模,200L)
  • III期临床: 500g-1kg(商业化规模,2000L)

7.6 Risk Assessment

7.6 风险评估

Manufacturing Risks:
RiskProbabilityImpactMitigation
Low expressionLowMediumCodon optimization, promoter engineering
AggregationLowHighOptimized formulation, process controls
Glycosylation heterogeneityMediumLowCHO cell line selection, process optimization
Charge variantsMediumLowProcess pH control, storage conditions
Overall Manufacturing Risk: Low (standard IgG process)
Source: CMC assessment, manufacturing predictions

---
生产风险:
风险概率影响缓解措施
低表达量密码子优化、启动子工程
聚集优化制剂配方、工艺控制
糖基化异质性CHO细胞株选择、工艺优化
电荷变体工艺pH控制、储存条件优化
整体生产风险: 低(标准IgG生产工艺)
来源: CMC评估, 生产预测

---

Phase 8: Final Report & Recommendations

阶段8: 最终报告与建议

Report Template

报告模板

markdown
undefined
markdown
undefined

Antibody Optimization Report: [ANTIBODY_NAME]

抗体优化报告: [抗体名称]

Generated: [Date] | Target: [Target Antigen] | Status: Complete

生成日期: [日期] | 靶点: [靶点抗原] | 状态: 完成

Executive Summary

执行摘要

[Summary of optimization strategy, key improvements, and recommendations...]
Top Candidate: [Variant name]
  • Humanization: 87% (from 62%)
  • Affinity: 1.2 nM (7x improvement)
  • Developability score: 82/100 (Tier 1)
  • Immunogenicity: Low risk
  • Manufacturing: Standard process
Recommendation: Advance to preclinical development

[优化策略、关键改进及建议摘要...]
最优候选变体: [变体名称]
  • 人源化程度: 87%(从62%提升)
  • 亲和力: 1.2 nM(提升7倍)
  • 成药性评分: 82/100(T1级)
  • 免疫原性: 低风险
  • 生产: 标准工艺
建议: 推进至临床前开发阶段

1. Input Characterization

1. 输入特征表征

[Section from Phase 1...]
[阶段1内容...]

2. Humanization Strategy

2. 人源化策略

[Section from Phase 2...]
[阶段2内容...]

3. Structure Modeling & Analysis

3. 结构建模与分析

[Section from Phase 3...]
[阶段3内容...]

4. Affinity Optimization

4. 亲和力优化

[Section from Phase 4...]
[阶段4内容...]

5. Developability Assessment

5. 成药性评估

[Section from Phase 5...]
[阶段5内容...]

6. Immunogenicity Prediction

6. 免疫原性预测

[Section from Phase 6...]
[阶段6内容...]

7. Manufacturing Feasibility

7. 生产可行性分析

[Section from Phase 7...]

[阶段7内容...]

8. Final Recommendations

8. 最终建议

8.1 Recommended Candidate

8.1 推荐候选变体

Variant: VH_Humanized_Affinity_Optimized_v3
Sequence:
>VH_v3 | Humanized 87%, Affinity optimized, Deimmunized
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMWGIIPIFGTANY
AQKFQGRVTMTTDTSTSSAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS

>VL_v3 | Humanized 90%
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK
变体: VH_Humanized_Affinity_Optimized_v3
序列:
>VH_v3 | 人源化87%, 亲和力优化, 去免疫原化
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMWGIIPIFGTANY
AQKFQGRVTMTTDTSTSSAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS

>VL_v3 | 人源化90%
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK

8.2 Key Improvements

8.2 关键改进

MetricOriginalOptimizedImprovement
Humanness62%87%+40%
Affinity (KD)5.2 nM0.8 nM6.5x
Developability62/10082/100+32%
Immunogenicity riskHighLow-70%
Stability (Tm)68°C74°C+6°C
Expression1.2 g/L2.0 g/L+67%
指标原始序列优化后序列提升幅度
人源化程度62%87%+40%
亲和力(KD)5.2 nM0.8 nM6.5倍
成药性评分62/10082/100+32%
免疫原性风险-70%
稳定性(Tm)68°C74°C+6°C
表达量1.2 g/L2.0 g/L+67%

8.3 Experimental Validation Plan

8.3 实验验证方案

Phase 1: In Vitro Characterization (3-4 months)
AssayPurposeTimeline
Affinity (SPR/BLI)Confirm KDWeek 1-2
Cell-based bindingTarget engagementWeek 2-3
Thermal stability (DSF)Tm measurementWeek 3
Aggregation (SEC)Monomer contentWeek 3-4
Expression (CHO)Titer confirmationWeek 4-8
Immunogenicity (in silico + PBMC)ADA predictionWeek 8-12
Phase 2: Lead Optimization (2-3 months)
  • Test backup variants if needed
  • Formulation development
  • Scale-up to 100mg
Phase 3: Preclinical Studies (6-12 months)
  • In vivo efficacy (tumor models)
  • PK/PD studies
  • Toxicology (GLP)
阶段1: 体外表征(3-4个月)
检测项目目的timeline
亲和力(SPR/BLI)验证KD值第1-2周
细胞水平结合实验靶点结合验证第2-3周
热稳定性(DSF)Tm值测定第3周
聚集分析(SEC)单体含量第3-4周
CHO表达验证滴度确认第4-8周
免疫原性预测(计算+PBMC)ADA风险预测第8-12周
阶段2: 先导优化(2-3个月)
  • 如需,测试备选变体
  • 制剂开发
  • 放大至100mg级
阶段3: 临床前研究(6-12个月)
  • 体内药效(肿瘤模型)
  • PK/PD研究
  • 毒理学研究(GLP)

8.4 Alternative Variants (Backup)

8.4 备选变体(备份)

VariantProfileRecommendation
VH_v2Higher humanness (90%) but lower affinity (1.8 nM)Backup if immunogenicity issues
VH_v4Highest affinity (0.5 nM) but lower developability (72/100)Research tool only
VH_v1Balanced (affinity 2.1 nM, dev 78/100)Second backup
变体特性建议
VH_v2人源化程度更高(90%)但亲和力较低(1.8 nM)若出现免疫原性问题则作为备份
VH_v4亲和力最高(0.5 nM)但成药性较低(72/100)仅作为研究工具
VH_v1性能均衡(亲和力2.1 nM, 成药性78/100)第二备份

8.5 Intellectual Property Considerations

8.5 知识产权考量

FTO Analysis Required:
  • Check existing patents on anti-[target] antibodies
  • CDR sequence novelty assessment
  • Humanization method IP landscape
Patentability:
  • Novel CDR-H3 sequence (14 aa, unique)
  • Specific humanization with affinity improvement
  • Combination of mutations (H100aY+H52W+L91E)
必需的FTO分析:
  • 检索针对[靶点]的现有抗体专利
  • CDR序列新颖性评估
  • 人源化方法的知识产权格局分析
可专利性:
  • 独特的CDR-H3序列(14 aa)
  • 特定的人源化+亲和力提升策略
  • 组合突变(H100aY+H52W+L91E)

8.6 Next Steps

8.6 下一步计划

Immediate (Month 1-3):
  1. Synthesize genes for VH_v3, VL_v3, and 2 backups
  2. Express in CHO cells (transient and stable)
  3. Purify and characterize (affinity, stability, aggregation)
  4. Confirm developability predictions
Short-term (Month 4-6):
  1. Develop stable CHO cell line (top candidate)
  2. Scale up to 500mg for in vivo studies
  3. Formulation development and stability studies
  4. Initiate in vivo efficacy studies
Long-term (Month 7-24):
  1. GMP manufacturing readiness
  2. IND-enabling studies (tox, CMC)
  3. File IND
  4. Phase 1 clinical trial

短期(第1-3个月):
  1. 合成VH_v3、VL_v3及2个备份变体的基因
  2. 在CHO细胞中表达(瞬时+稳定转染)
  3. 纯化并表征(亲和力、稳定性、聚集性)
  4. 验证成药性预测结果
中期(第4-6个月):
  1. 开发候选变体的稳定CHO细胞株
  2. 放大至500mg级用于体内研究
  3. 制剂开发及稳定性研究
  4. 启动体内药效研究
长期(第7-24个月):
  1. GMP生产准备
  2. IND申报研究(毒理、CMC)
  3. 提交IND申请
  4. I期临床试验

9. Data Sources & Tools Used

9. 数据来源与工具

ToolPurposeQueries
IMGTGermline identificationIGHV, IGKV genes
TheraSAbDabClinical precedentsAnti-[target] antibodies
AlphaFoldStructure predictionVH-VL complex
IEDBImmunogenicityEpitope prediction
SAbDabStructural analysisPDB structures
UniProtTarget information[Target accession]

---
工具用途查询内容
IMGT种系基因识别IGHV、IGKV等基因
TheraSAbDab临床先例查询抗[靶点]抗体
AlphaFold结构预测VH-VL复合物
IEDB免疫原性预测表位预测
SAbDab结构分析PDB结构
UniProt靶点信息获取[靶点编号]

---

Evidence Grading System

证据分级体系

TierSymbolCriteria
T1★★★Humanness >85%, KD <2 nM, Developability >75, Low immunogenicity
T2★★☆Humanness 70-85%, KD 2-10 nM, Developability 60-75, Medium immunogenicity
T3★☆☆Humanness <70%, KD >10 nM, Developability <60, or High immunogenicity
T4☆☆☆Failed validation or major liabilities

等级符号标准
T1★★★人源化程度>85%, KD<2 nM, 成药性评分>75, 低免疫原性
T2★★☆人源化程度70-85%, KD2-10 nM, 成药性评分60-75, 中免疫原性
T3★☆☆人源化程度<70%, KD>10 nM, 成药性评分<60, 或高免疫原性
T4☆☆☆验证失败或存在重大缺陷

Completeness Checklist

完整性检查清单

Phase 1: Input Analysis

阶段1: 输入分析

  • Sequence annotated (CDRs, frameworks)
  • Species identified
  • Target antigen characterized
  • Clinical precedents identified
  • 序列已注释(CDR、框架区)
  • 物种已识别
  • 靶点抗原已表征
  • 临床先例已查询

Phase 2: Humanization

阶段2: 人源化

  • Germline genes identified (IMGT)
  • Framework selected
  • CDR grafting designed
  • Backmutations analyzed
  • ≥2 humanized variants designed
  • 种系基因已识别(IMGT)
  • 框架区已选择
  • CDR移植已设计
  • 回复突变已分析
  • 已设计≥2种人源化变体

Phase 3: Structure

阶段3: 结构分析

  • AlphaFold structure predicted
  • CDR conformations analyzed
  • Epitope mapped
  • Structural quality assessed
  • AlphaFold结构已预测
  • CDR构象已分析
  • 表位已定位
  • 结构质量已评估

Phase 4: Affinity

阶段4: 亲和力优化

  • Current affinity estimated
  • Affinity mutations proposed
  • CDR optimization strategies identified
  • Testing plan outlined
  • 当前亲和力已预估
  • 亲和力突变已建议
  • CDR优化策略已识别
  • 测试方案已制定

Phase 5: Developability

阶段5: 成药性评估

  • Aggregation assessed
  • PTM sites identified
  • Stability predicted
  • Expression predicted
  • Overall score calculated (0-100)
  • 聚集性已评估
  • PTM位点已识别
  • 稳定性已预测
  • 表达量已预测
  • 已计算综合成药性评分(0-100)

Phase 6: Immunogenicity

阶段6: 免疫原性预测

  • T-cell epitopes predicted (IEDB)
  • Immunogenicity score calculated
  • Deimmunization strategy proposed
  • Clinical precedent comparison
  • T细胞表位已预测(IEDB)
  • 免疫原性评分已计算
  • 去免疫原化策略已建议
  • 临床先例已对比

Phase 7: Manufacturing

阶段7: 生产可行性

  • Expression system assessed
  • Purification strategy outlined
  • Formulation recommended
  • CMC timeline estimated
  • 表达系统已评估
  • 纯化策略已制定
  • 制剂配方已推荐
  • CMC周期已预估

Phase 8: Final Report

阶段8: 最终报告

  • Ranked variant list
  • Top candidate recommended
  • Experimental validation plan
  • Backup variants identified
  • Next steps outlined

  • 变体排名列表已生成
  • 最优候选变体已推荐
  • 实验验证方案已制定
  • 备份变体已识别
  • 下一步计划已制定

Tool Reference

工具参考

IMGT Tools

IMGT工具

  • IMGT_search_genes
    : Search germline genes (IGHV, IGKV, etc.)
  • IMGT_get_sequence
    : Get germline sequences
  • IMGT_get_gene_info
    : Database information
  • IMGT_search_genes
    : 搜索种系基因(IGHV、IGKV等)
  • IMGT_get_sequence
    : 获取种系序列
  • IMGT_get_gene_info
    : 数据库信息查询

Antibody Databases

抗体数据库

  • SAbDab_search_structures
    : Search antibody structures
  • SAbDab_get_structure
    : Get structure details
  • TheraSAbDab_search_therapeutics
    : Search by name
  • TheraSAbDab_search_by_target
    : Search by target antigen
  • SAbDab_search_structures
    : 搜索抗体结构
  • SAbDab_get_structure
    : 获取结构详情
  • TheraSAbDab_search_therapeutics
    : 按名称搜索临床抗体
  • TheraSAbDab_search_by_target
    : 按靶点抗原搜索

Immunogenicity

免疫原性工具

  • iedb_search_epitopes
    : Search epitopes
  • iedb_search_bcell
    : B-cell epitopes
  • iedb_search_mhc
    : MHC-II epitopes
  • iedb_get_epitope_references
    : Citations
  • iedb_search_epitopes
    : 搜索表位
  • iedb_search_bcell
    : B细胞表位查询
  • iedb_search_mhc
    : MHC-II表位查询
  • iedb_get_epitope_references
    : 引用文献查询

Structure & Target

结构与靶点工具

  • AlphaFold_get_prediction
    : Structure prediction
  • UniProt_get_protein_by_accession
    : Target info
  • PDB_get_structure
    : Experimental structures
  • AlphaFold_get_prediction
    : 结构预测
  • UniProt_get_protein_by_accession
    : 靶点信息查询
  • PDB_get_structure
    : 实验结构获取

Systems Biology (for Bispecifics)

系统生物学工具(双特异性抗体)

  • STRING_get_interactions
    : Protein interactions
  • STRING_get_enrichment
    : Pathway analysis

  • STRING_get_interactions
    : 蛋白质相互作用分析
  • STRING_get_enrichment
    : 通路分析

Special Considerations

特殊考量

Bispecific Antibody Engineering

双特异性抗体工程

  • Use STRING tools to identify co-expressed targets
  • Design separate binding arms for each target
  • Consider asymmetric formats (e.g., CrossMAb, DuoBody)
  • Assess aggregation risk (higher for bispecifics)
  • 使用STRING工具识别共表达靶点
  • 为每个靶点设计独立的结合臂
  • 考虑不对称格式(如CrossMAb、DuoBody)
  • 评估聚集风险(双特异性抗体风险更高)

pH-Dependent Binding

pH依赖性结合

  • Add His residues at interface (pKa ~6.0)
  • Target: Bind at pH 7.4, release at pH 6.0
  • Improves PK via FcRn recycling
  • Useful for tumor targeting (acidic microenvironment)
  • 在结合界面添加组氨酸残基(pKa~6.0)
  • 目标: pH7.4下结合,pH6.0下解离
  • 通过FcRn循环改善药代动力学
  • 适用于肿瘤靶向(酸性微环境)

Affinity Ceiling

亲和力上限

  • Most therapeutic antibodies: KD 0.1-10 nM
  • <0.1 nM: May cause target-mediated clearance
  • 1-5 nM: Sweet spot for most targets
  • Balance affinity vs. developability
  • 大多数治疗性抗体的KD值范围: 0.1-10 nM
  • <0.1 nM: 可能导致靶点介导的清除
  • 1-5 nM: 大多数靶点的最优范围
  • 平衡亲和力与成药性
undefined